Ordered by the (chief) executive Makers of weight-loss drugs, the hottest segment of the pharmaceutical market just now, weren't looking so hot on the stock exchange Tuesday. A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement levels. The company most associated with obesity treatments, Denmark-based Novo Nordisk (NVO -3.40%), closed the day with a nearly 4% drop in its share price. Two would-be rivals currently hard at work trying to bring ...